共查询到17条相似文献,搜索用时 93 毫秒
1.
目的 探讨血小板/淋巴细胞比值(PLR)对急性ST段抬高型心肌梗死(STEMI)患者经皮冠脉介入术(PCI)后心肌无复流的预测价值。方法 选取2014年10月—2018年10月蚌埠市第二人民医院收治的STEMI患者118例,详细记录病史和体格检查结果,检测血小板计数(PLT)、淋巴细胞计数(LY),计算PLR;评估PCI术中情况,记录术中梗死相关动脉的病变情况,采用Gensini积分评价冠状动脉病变程度,采用TIMI血流分级将患者分为正常复流组(TIMI 3级)和无复流组(TIMI 0~2级)。结果 两组患者年龄、性别构成比、高血压、糖尿病、吸烟、卒中、发病时间、Killip分级构成比比较,差异均无统计学意义(P?>0.05);无复流组患者PLT、PLR和Gensini积分高于正常复流组(P?<0.05),其余指标两组间比较,差异均无统计学意义(P?>0.05),相关性分析显示PLR与Gensini积分呈正相关(r?=0.581,P?=0.006);多因素Logistic回归结果显示:PLR高[OlR=2.737(95% CI:1.433,5.227)]和Gensini积分高[OlR=1.490(95% CI:1.087,2.042)]为影响PCI术后心肌无复流的危险因素。ROC曲线分析结果显示以PLR为诊断模型变量,曲线下面积为0.751,以最大约登指数计算的诊断阈值为188.21,预测无复流的敏感性为70%,特异性为73%。结论 PLR与STEMI患者冠状动脉病变程度呈正相关,PLR对PCI术后心肌无复流具有一定的的预测价值。 相似文献
2.
目的探讨急诊经皮冠状动脉介入(PCI)治疗冠状动脉(冠脉)无复流患者的左室功能。方法回顾性分析本院自1998年1月~2004年12月97例急性ST段抬高心肌梗死(STEMI)直接PCI患者的临床和影像资料。急诊PCI支架置入即刻,在无影响血流的血栓、栓塞、夹层、痉挛情况下,冠脉造影前向血流小于或等于TIMI 2级为无复流,TIMI 3级为正常血流。冠脉无复流患者13例,从其余84例急诊PCI冠脉前向血流恢复正常的同期患者中随机抽取15例,为正常血流组。结果无复流和正常血流患者的肌酸肌酶峰值、Killip心功能分级、Q波计数、WMS差异有统计学意义(P<0.05)。正常血流患者术后4周WMS改善,LVEF、CI、SVI增加,差异有统计学意义(P<0.05)。随访2年,无复流组死亡3例(1例猝死,2例死于心力衰竭),正常血流组1例因呼吸衰竭死亡。结论无复流患者的心肌损害严重,梗死或濒临坏死的心肌范围广泛,室壁运动恢复较慢,局部心肌功能不良,左室舒缩功能降低。冠脉无复流是急诊PCI患者左室功能不全和心血管事件独立的预测因素。 相似文献
3.
4.
冠状动脉粥样硬化性心脏病是全球范围内心血管疾病患者死亡的主要原因,其中以急性ST段抬高型心肌梗死(STEMI)最为凶险。及时经皮冠状动脉介入治疗(PCI)是目前急性STEMI患者最主流的再灌注策略。而部分患者在PCI术后仍不能得到充分的血液灌注,即出现无复流现象(NRP),与随后的不良临床预后密切相关。因此,为了有效恢复再灌注后冠状动脉微循环的血流,防治冠状动脉NRP的发生就显得尤为重要。本文回顾NRP的定义、诊断和临床表现,以病理生理机制为桥梁,提出通过相关预测因子来选择防治策略从而提高PCI疗效。 相似文献
5.
目的 探讨急性ST段抬高心肌梗死(ST-segment elevation myocardial infarction,STEMI)患者行急诊冠状动脉介入术(percutaneous coronary intervention,PCI)中发生无复流的影响因素。方法 将2012年6月至2013年1月本院收治的行急诊PCI治疗的急性STEMI患者(n=92),分为正常复流组(n=73)和无复流组(n=19)。通过比较两组的临床症状来分析无复流发生的相关影响因素。结果 急性STEMI患者行急诊PCI后无复流发生率为20.7%(19/92),无复流组与正常复流组相比,两组之间入院时的收缩压(SBP)、2型糖尿病患病数、肌钙蛋白T峰值、发病到再灌注时间、球囊扩张次数和靶血管植入支架数量差异均有统计学意义(P<0.05);经多因素logistic 回归分析显示入院SBP<100 mmHg (1 mmHg=0.133 kPa)、合并2型糖尿病、球囊扩张次数、肌钙蛋白T峰值、右冠状动脉病变和发病至再灌注时间是急诊PCI术后无复流发生的危险因素。结论 急性STEMI患者行急诊PCI后无复流发生与入院SBP<100 mmHg、合并2型糖尿病、球囊扩张次数、肌钙蛋白T峰值、右冠状动脉病变及发病至再灌注时间这6种临床因素具有相关性。 相似文献
6.
作为急性心肌梗死(acute myocardial infarction,AMI)后再灌注治疗的有效方法,经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗能使梗死相关动脉得到快速、完全和持久的开通,从而达到缩小梗死范围,保持心室功能,降低死亡率,改善患者预后和提高生活质量的目的[1]。但临床观察发现 相似文献
7.
急性ST段抬高型心肌梗死(acute ST-segment elevation myocardial infarction, STEMI)是世界范围内心血管疾病患者死亡的主要原因,及时开通相关动脉是最有效的治疗手段。通过经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)开通罪犯血管是急性STEMI的首选再灌注策略,然而,约半数患者PCI术后仍得不到充分的微循环灌注,出现无复流现象(no-reflow phenomenon, NRP),这与不良心血管事件的发生密切相关。现综述PCI术后NRP药物治疗和非药物治疗的研究进展。 相似文献
8.
目的 探究血栓抽吸联合替罗非班及硝普钠对急性ST段抬高型心肌梗死(STEMI)患者球囊后扩张相关性无复流的预防效果。方法 收集发病12 h内急诊行经皮冠状动脉介入术(percutaneous coronary intervention,PCI),并进行球囊后扩张的STEMI患者254例,根据是否进行球囊后扩张相关性无复流的预防分为常规后扩张组和优化后扩张组[147例,男117例,女30例,平均年龄(63.39±13.84)岁]和优化后扩张组[107例,男86例,女21例,平均年龄(63.11±11.34)岁],优化后扩张组依据TIMI血栓积分结果进行血栓抽吸及预防性用药。比较两组临床资料、造影特征、介入治疗后疗效及术后1年主要心血管不良事件的差异。结果 常规后扩张组与优化后扩张组基本临床资料及造影特征差异无统计学意义。优化后扩张组球囊后扩张相关性无复流发生率(2.80%)低于常规后扩张组(10.88%),差异具有统计学意义(P=0.016)。优化后扩张组2 h内ST段回落 ≥ 50%的比例(87.85%)高于常规后扩张组(77.55%),差异具有统计学意义(P=0.047)。两组间术后24 h内心绞痛比例、CK-MB峰值及心功能指标(LVEF、LVEDD)差异均无统计学意义。优化后扩张组术后1年因心衰再住院的比例(0.93%)低于常规后扩张组(6.12%),两组间差异有统计学意义(P=0.048)。术后1年其他MACE事件(IRA导致的再发心绞痛、IRA再次血运重建、心源性死亡)发生比例及心功能指标(LVEF、LVEDD)两组间差异均无统计学意义。结论 STEMI患者预防性应用血栓抽吸联合替罗非班及硝普钠,有助于降低球囊后扩张相关性无复流的发生,有效提高PCI术后疗效,减少心血管不良事件发生。 相似文献
9.
目的:探讨血小板淋巴细胞比值(PLR)是否与急性ST段抬高性心肌梗死(STEMI)相关。方法:选择2017年1月1日—2018年12月31日在心内科因急性STEMI住院行急诊冠状动脉介入治疗的患者,采用倾向性评分方法匹配对照组,分析PLR与STEMI的相关性。结果:STEMI组PLR水平显著高于对照组(165.43±81.63、121.72±57.64,P<0.05)。Logistic回归结果显示PLR是STEMI的独立危险因素[P=0.027,OR(95%CI)=3.486(1.149~10.582)]。ROC曲线下面积为0.689,当PLR的cut-off值为129.59时诊断效率最高,敏感度62.4%,特异度70.1%。结论:PLR与STEMI独立相关,是STEMI有效预测指标。 相似文献
10.
目的探讨ST段抬高型急性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中无复流现象发生的原因及处理方法。方法回顾性分析43例STEMI患者急诊PCI治疗中无复流现象的发生情况。结果43例患者中,梗死相关血管(IRA)为右冠状动脉者27例(62.8%),前降支13例(30.2%),回旋支3例(7.0%);无复流患者的平均再灌注时间为(5.7±2.8)h。无复流患者给予盐酸地尔硫艹卓、腺苷、溶栓剂等药物治疗和主动脉内反搏泵(IABP)治疗。43例患者中,术中及住院期间共死亡6例,病死率为14.0%。结论无复流现象是STEMI患者PCI治疗中常见的合并症之一,有较高的病死率;药物和IABP的综合治疗对无复流患者有一定的疗效。 相似文献
11.
本研究对急性心肌梗死(AMI)患者再灌注无复流现象进行探讨。分析无复流发生的相关因素,并测定AMI患者再灌注治疗前后血栓调节蛋白(TM)水平,探讨冠脉微栓塞在再灌注后无复流发生机制中的作用,通过研究再灌注后无复流患者血浆TM水平的变化以期为冠脉微栓塞致无复流提供筛查参考依据。 相似文献
12.
Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction 总被引:2,自引:0,他引:2
PAN Wei WANG Lan-feng YU Jia-hui FAN Ying YANG Shu-sen ZHOU Li-jun LI Yue LI Wei-min 《中华医学杂志(英文版)》2009,122(22):2718-2723
Background No-reflow phenomenon during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is a predictive factor of continuous myocardial ischemia, ventricular remodeling and cardiac dysfunction, which is closely associated with a worse prognosis. This study aimed to evaluate intracoronary nitroprusside in the prevention of the no-reflow phenomenon in AMI.
Methods Ninety-two consecutive patients with AMI, who underwent primary PCI within 12 hours of onset, were randomly assigned to 2 groups: intracoronary administration of nitroprusside (group A, n=46), intracoronary administration of nitroglycerin (group B, n=46). The angJographic results were observed. The real-time myocardial contrast echocardiography (RT-MCE), including contrast score index (CSI), wall motion score index (WMSI), transmural contrast defect length (CDL) and serious WM abnormal length (WML) were recorded at 24 hours and 1 week post-PCI. High sensitivity C-reactive protein (Hs-CRP) was examined by immune rate nephelometry. N-terminal prohormone brain natriuretic peptide (NT-proBNP) was tested with enzyme-linked immunosorbent assay. Patients were followed up for six months. Major adverse cardiac events (MACE) were recorded. Results The incidence of final TIMI-3 flow in group A was much higher than that in Group B (P 〈0.05), final corrected TIMI frame count (cTFC) in group A decreased significantly than that in group B (P 〈0.01). The CSI, CDL/LV length, WMSI and WL/LV length in group A were significantly lower than that in group B (P 〈0.01). Levels of Hs-CRP and NT-proBNP at 1 week post-PCI decreased significantly in group A than that in group B (P 〈0.01). Patients were followed up for 6 months and the incidence of MACE in group A was significantly lower than that in group B (P〈0.05).
Conclusion Intracoronary nitroprusside can improve myocardial microcirculation, leading to the decrease of the incidence of no-reflow phenomenon and better prognosis. 相似文献
Methods Ninety-two consecutive patients with AMI, who underwent primary PCI within 12 hours of onset, were randomly assigned to 2 groups: intracoronary administration of nitroprusside (group A, n=46), intracoronary administration of nitroglycerin (group B, n=46). The angJographic results were observed. The real-time myocardial contrast echocardiography (RT-MCE), including contrast score index (CSI), wall motion score index (WMSI), transmural contrast defect length (CDL) and serious WM abnormal length (WML) were recorded at 24 hours and 1 week post-PCI. High sensitivity C-reactive protein (Hs-CRP) was examined by immune rate nephelometry. N-terminal prohormone brain natriuretic peptide (NT-proBNP) was tested with enzyme-linked immunosorbent assay. Patients were followed up for six months. Major adverse cardiac events (MACE) were recorded. Results The incidence of final TIMI-3 flow in group A was much higher than that in Group B (P 〈0.05), final corrected TIMI frame count (cTFC) in group A decreased significantly than that in group B (P 〈0.01). The CSI, CDL/LV length, WMSI and WL/LV length in group A were significantly lower than that in group B (P 〈0.01). Levels of Hs-CRP and NT-proBNP at 1 week post-PCI decreased significantly in group A than that in group B (P 〈0.01). Patients were followed up for 6 months and the incidence of MACE in group A was significantly lower than that in group B (P〈0.05).
Conclusion Intracoronary nitroprusside can improve myocardial microcirculation, leading to the decrease of the incidence of no-reflow phenomenon and better prognosis. 相似文献
13.
目的 探讨急性ST段抬高型心肌梗死(acute ST-segment elevation myocardial infarction,ASTEMI)患者术前服用负荷量替格瑞洛对急诊经皮冠状动脉介入(percutaneous coronary interventions,PCI)术中冠状动脉血流及预后的影响.方法 将127例ASTEMI并行急诊PCI患者分为替格瑞洛组(n=62)及氯吡格雷组(n=65),术前分别给予替格瑞洛180 mg、氯吡格雷600 mg,比较两组基本情况、术后冠脉血流及术后6个月主要心血管不良事件,包括急性及亚急性支架内血栓、再发心绞痛及心肌梗死、“罪犯”血管再次血运重建、再次住院和死亡等.结果 氯吡格雷组与替格瑞洛组基本临床资料、冠脉造影情况、术后心肌酶峰值及左室射血分数差异均无统计学意义(P>0.05);氯吡格雷组与替格瑞洛组术后梗死相关血管无复流发生率(分别为15.2%、3.2%)、校正TIMI血流帧数计数[分别为(28.4±13.6)、(23.2±7.4)帧]、术后心肌酶达峰时间[分别为(19.0±8.3)、(16.0 ±5.9)h]、2h心电图ST段回落指数≥50%比例(分别为76.9%、91.9%)差异有统计学意义(P<0.05);替格瑞洛组6个月随访复合终点事件发生率较氯吡格雷组明显降低(P<0.05).结论 急诊PCI前负荷量替格瑞洛可明显改善梗死相关血管冠脉血流、心肌灌注及临床预后. 相似文献
14.
目的测定AMI患者再灌注治疗前后血栓调节蛋白(TM)水平。方法对60例我院急诊确诊AMI患者.通过临床调查和病历记载记录患者的一般情况、危险因素及伴发疾病.在就诊时、再灌注治疗后第3d采集血标本,应用固相夹心法酶联免疫吸附试验(EUSA)测定AMI患者和健康对照组血浆TM水平。结果AMI患者再灌注治疗前后血浆TM水平均高于健康对照组(P〈0.05),无复流患者就诊时TM水平高于再灌流组(P〈0.05),再灌注治疗后第3d两组间差异更显著(P〈0.01)。结论血浆TM水平可反映AMI患者再灌注治疗前后血管内皮损伤程度;无复流患者血浆TM水平明显升高。 相似文献
15.
Wang Yanfei Yao Min Liu Haibo Yang Yuejin Xie Junmin Jia Xinwei Pan Huanjun Wang Chunyan 《中华医学杂志(英文版)》2014,127(6):1008-1011
Background Balloon release pressure may increase the incidence of no reflow after direct percutaneous coronaryintervention (PCI). This randomized controlled study was designed to analyze the correlation between balloon releasepressure and no-reflow in patients with acute myocardial infarction (AMI) undergoing direct PCI.Methods There were 156 AMI patients who underwent PCI from January 1, 2010 to December 31, 2012, and weredivided into two groups according to the stent inflation pressure: a conventional pressure group and a high pressure group.After PCI, angiography was conducted to assess the thrombolysis in myocardial infarction (TIMI) grade with related artery.Examinations were undertaken on all patients before and after the operation including cardiac enzymes, total cholesterol,low-density lipoprotein, blood glucose, homocysteine, 13-thromboglobulin (I3-TG), Hamilton depression scale (HAMD) andself-rating anxiety scale (SAS). After interventional therapy, the afore-mentioned parameters in both the conventionalpressure group and high pressure group were again analyzed.Results The results showed that CK-MB, HAMD, SAS were significantly different (P 〈0.05) in all patients after PCI,especially the CK-MB in the high pressure group ((25.7_+7.6) U/L vs. (76.7+11.8) U/L). CK-MB, HAMD, SAS, and I3-TGwere comparative before PCI but they were significantly changed (P 〈0.05) after intervention. No-reflow phenomenonoccurred in 13 patients in the high pressure group, which was significantly higher than in the conventional pressure group(17.11% vs. 6.25%, P 〈0.05).Conclusion In stent implantation, using a pressure less than 1823.4 kPa balloon to release pressure may be the betterchoice to reduce the occurrence of no-reflow followinq direct PCI. 相似文献
16.
目的 探讨体质量指数(BMI)对急性ST段抬高型心肌梗死(STEMI)患者预后的影响.方法 回顾性收集该院2014年收治的STEMI住院患者的临床资料,将患者根据BMI分为4组:低体质量组(n=31)、正常体质量组(n=139)、超重组(n=71)和肥胖组(n=26),对比分析4组患者的临床基线资料,并随访心肌梗死后7d和年内的全因死亡率.结果 BMI越高患者发病年龄越轻(P<0.01),女性所占比例越小(P =0.001),其中肥胖组患者的清蛋白水平、血红蛋白水平均相对较高(P=0.004;P=0.006);心肌梗死后1年的全因死亡率随着BMI升高而明显降低(P=0.003),心肌梗死后7d的全因死亡率差异无统计学意义(P=0.287).结论 BMI与STEMI患者的远期预后相关,“肥胖矛盾”现象在STEMI患者中是存在的,但应结合患者年龄、性别、并发症和药物治疗等多个因素综合评估BMI对STEMI患者预后的影响. 相似文献
17.
目的:探讨中性粒细胞/淋巴细胞比率(NLR)与急性心肌梗死(AMI)患者临床并发症之间的关系. 方法:入选急性ST段抬高心肌梗死(STEMI)患者218例,入院后即刻抽取静脉血查血常规,按中性粒细胞/淋巴细胞比率的大小由小到大将其分为A、B两组,对两组急性心肌梗死并发症发生率进行比较. 结果:两组肌钙蛋白峰值分别为(32.5±21.7)ng/ml和(56.8±39.4)ng/ml,B组高于A组,差异具有统计学意义(P<0.01).心律失常(17.43%和39.45%,P<0.01)、心力衰竭(22.94%和51.38%,P<0.01)及猝死发生率(2.75%和11.01%,P<0.05)B组均显著高于A组,差异具有统计学意义.多元逐步回归分析显示NLR与AMI并发症发生率具有显著的相关性(P<0.05).结论:中性粒细胞/淋巴细胞比率是急性心肌梗死患者临床并发症的可靠预测指标. 相似文献